hyperbilirubinemia


Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

hyperbilirubinemia

[¦hī·pər‚bil·ə‚rü·bə′nē·mē·ə]
(medicine)
Excessive amounts of bilirubin in the blood.
A severe, prolonged physiologic jaundice.
References in periodicals archive ?
The present study concludes that breast feeding/nonfeeding is the most common cause of neonatal hyperbilirubinemia in areas near Shri Ram Murti Smarak Institute Of Medical Sciences, a tertiary care teaching hospital, followed by other causes like breast milk jaundice, jaundice due to prematurity, neonatal sepsis, neonatal hypothyroidism, Congenital biliary atresia & ABO incompatibility.
Hyperbilirubinemia in full-term infants has become an uncommon event in the last 30 years, as the result of the recognition of and early prenatal intervention in Rh-negative mothers and the widespread use of Rho (D) immune globulin (RhoGAM), exchange transfusions, and phototherapy.
Our study studied the effects of phototherapy on major serum electrolytes in neonates being treated for hyperbilirubinemia and noted statistically significant results.
Term and late-preterm babies, who received phototherapy due to hyperbilirubinemia in the Neonatal Intensive Care Unit of Marmara University Medical Faculty between January 2015 and December 2015, were enrolled in this prospective study.
Incidence of neonatal hyperbilirubinemia: a population-based prospective study in Pakistan.
If their serum bilirubin level was greater than 12.9 mg/dL, they were identified as having hyperbilirubinemia.
Clinical Significance of Hyperbilirubinemia Among HIV-1-Infected Patients Treated with Atazanavir/Ritonavir Through 96 Weeks in the CASTLE Study.
KEYWORDS: Cholestasis, Hyperbilirubinemia, Vitamin B12 deficiency.
The present case had severe metabolic acidosis with a high anionic gap, severe hemolytic anemia, hyperbilirubinemia, and high levels of 5-oxoprolinuria.
Neonatal hypoglycemia, hyperbilirubinemia, intensive care unit admission, large-for-gestational-age (LGA) and small-for-gestational-age (SGA) newborns were considered as adverse outcomes.
drug is expected to become the first and only pharmacologic option in the US indicated for treatment of neonates at risk for developing severe hyperbilirubinemia, or severe jaundice.
Most of this newborn hyperbilirubinemia is a natural transition which resolves by the first week of life with maturing of the liver.